ERBB2 and triple-negative breast carcinoma: In such a delicate setting, current guidelines advise for neoadjuvant chemotherapy (NACT) as primary treatment [1], especially for subtypes where the need for systemic therapy is mandatory in the adjuvant setting, such as human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancers (TNBC) [1,4,5].